Search
Menu
Bristol Instruments, Inc. - 872 Series High-Res 4/24 LB

Daily News Briefs

Facebook X LinkedIn Email
Bristol-Myers Squibb Medical Imaging Inc. and Kereos Inc. have entered into agreements to develop and commercialize novel molecular imaging agents to detect cardiovascular diseases and cancer. Bristol-Myers Squibb Medical Imaging has obtained exclusive worldwide rights to develop and commercialize select cardiovascular molecular imaging agents for magnetic resonance imaging, and Kereos, based in St. Louis, Mo., has obtained rights to use Bristol-Myers Squibb Medical Imaging's targeting molecules with its core technology to develop molecular cancer imaging agents and targeted therapeutics....Read full article

Related content from Photonics Media



    Articles


    Products


    Photonics Handbook Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories


    Companies
    Published: March 2004
    Bristol-Myers Squibb Medical ImagingDalsadefenseKereosmolecular imagingNews BriefsPhotonics Tech BriefsSensors & Detectorsspectroscopy

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.